1-2 of 2
Akash Nahar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla
Journal: Blood Advances
Blood Adv (2022) 6 (2): 590–599.
https://doi.org/10.1182/bloodadvances.2021004970
Published: 2022
Includes: Supplemental data
Journal Articles

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Clinical Trials & Observations
Philippe Armand, John Kuruvilla, Jean-Marie Michot, Vincent Ribrag, Pier Luigi Zinzani, Ying Zhu, Patricia Marinello, Akash Nahar, Craig H. Moskowitz
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2617–2622.
https://doi.org/10.1182/bloodadvances.2019001367
Published: 2020
Includes: Supplemental data